FORCED TITRATION STUDY OF TEVETEN ENALAPRIL IN AFRICAN AMERICANS W/ H
$14,791M01FY2000RRNIH
University Of Rochester, Rochester NY
Investigators
Linked publications & trials
Paper 37567038Paper 35728925Paper 33759672Paper 33478957Paper 33002231Paper 32446491Paper 31570296Paper 31554845Paper 31505070Paper 31404238Paper 30381795Paper 29872859Paper 28279433Paper 28199816Paper 27923864Paper 27839954Paper 27601618Paper 27423510Paper 27074126Paper 26080344Paper 25862953Paper 25422979Paper 25377444Paper 25367540Paper 25061144Paper 24471562Paper 24378638Paper 24370654Paper 24322171Paper 24144899Paper 24135709Paper 23944767Paper 23646844Paper 23615642Paper 23503447Paper 23370608Paper 23255294Paper 23080542Paper 23055555Paper 22981277Paper 22871201Paper 22684193Paper 22644414Paper 22499082Paper 22415562Paper 22257000Paper 22180621Paper 22113871Paper 22083073Paper 22059091Paper 22018086Paper 21960671Paper 21956833Paper 21941167Paper 21930284Paper 21900636Paper 21798559Paper 21382516Paper 21364200Paper 21293986Paper 21233301Paper 21181521Paper 21149431Paper 21135351Paper 20921898Paper 20871389Paper 20827170Paper 20711481Paper 20650002Paper 20647396Paper 20622678Paper 20601666Paper 20592644Paper 20581335Paper 20542294Paper 20507211Paper 20467286Paper 20439846Paper 20400411Paper 20356575Paper 20298818Paper 20237308Paper 20218880Paper 20211581Paper 20192725Paper 20088693Paper 20063429Paper 20025358Paper 19948631Paper 19938945Paper 19934383Paper 19890073Paper 19779585Paper 19770624Paper 19755933Paper 19750543Paper 19713112Paper 19690614Paper 19597072Paper 19536490
Abstract
The purpose of this study is to compare the safety and effectiveness of Teveten taken orally once daily, to that of a placebo and an approved and marketed antihypertensive drug, enalapril, over a 12 week period. This protocol will study African-American patients with essential hypertension during usual salt intake and with salt supplementation.
View original record on NIH RePORTER →